alpha-MSH is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-08-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Lyophilized peptide material is generally stored at -20 °C or below to limit degradation, while reconstituted solutions are less stable and are typically kept refrigerated and protected from light. Repeated freeze-thaw cycles can accelerate aggregation and should be minimized. Stability for any specific lot depends on purity, moisture content, and packaging. Handling in a temperature-controlled environment reduces variability across replicates, and exposure to ambient humidity during weighing can introduce error. Aliquotting reduces the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
| Property | Value | Notes |
|---|---|---|
| Storage form | Lyophilized powder | Longer stability at -20 °C |
| Reconstitution solvent | Sterile water or buffer | Depends on intended application |
| Purity assessment | Reverse-phase HPLC | Reported as peak area percentage |
| Identity confirmation | Mass spectrometry | Compared against theoretical mass |
| Main stability concern | Repeated freeze-thaw | May promote aggregation |
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
== Release == The film premiered at the 62nd Cannes Film Festival on 18 May 2009, and went on to screen at festivals such as the Toronto International Film Festival and the Maryland Film Festival. It was released in Greece on 11 November 2009 by Feelgood Entertainment. Verve Pictures acquired distribution rights for the United Kingdom and released it on 23 April 2010. Kino International released it in the United States on 25 June 2010.
== Research == Halliwell is known for his work on the control of free radicals in biological systems. His earliest research was in plants, where with Christine Foyer and others in 1976, he discovered the glutathione–ascorbate cycle (also known as the Foyer–Halliwell–Asada pathway) by which chloroplasts remove damaging hydrogen peroxide. He subsequently focused on the role of free radicals in human diseases, demonstrating the toxicity of the hydroxyl radical, a metabolite of superoxide, and investigated the involvement of metal ions, including iron and zinc, in this process, as well as the protective effect of their sequestration. He has also worked on reactive nitrogen species. He developed methods to measure free radical levels in vivo and to quantify the damage they cause to DNA. He has also researched dietary antioxidants. As of 2025, his research focuses on the role of free radicals and antioxidants in human disease, particularly Alzheimer's disease and other brain disorders. His interests include the characterisation of redox biomarkers for the identification of human diseases, molecular nutrition, the role of transition metal ions as promoters of radical reactions in vitro and in vivo, the development of drugs to prevent oxidative cell damage, the chemical nature of antioxidants in vivo, methods for the specific detection of reactive oxygen and reactive nitrogen species in vivo and their application to human disease, particularly stroke and neuro-degenerative diseases and ageing in humans and in the nematode Caenorhabditis elegans.
C3Cl4 + AlCl3 → [C3Cl3]+AlCl−4 Tetrachlorocyclopropene can be converted to tris(tert-butyldimethylsilyl)cyclopropene. Hydride abstraction with nitrosonium tetrafluoroborate yields the trisilyl-substituted cyclopropenium cation.
Biochanin A is an O-methylated isoflavone. It is a natural organic compound in the class of phytochemicals known as flavonoids. Biochanin A can be found in red clover in soy, in alfalfa sprouts, in peanuts, in chickpea (Cicer arietinum) and in other legumes. Biochanin A is classified as a phytoestrogen. It has also been found to be a weak inhibitor of fatty acid amide hydrolase in vitro.
Sources: en.wikipedia.org
The binding energy of the nucleus is the difference between the rest-mass energy of the nucleus and the rest-mass energy of the neutron and proton nucleons. The binding energy formula includes volume, surface and Coulomb energy terms that include empirically derived coefficients for all three, plus energy ratios of a deformed nucleus relative to a spherical form for the surface and Coulomb terms. Additional terms can be included such as symmetry, pairing, the finite range of the nuclear force, and charge distribution within the nuclei to improve the estimate. Normally binding energy is referred to and plotted as average binding energy per nucleon. According to Lilley, "The binding energy of a nucleus B is the energy required to separate it into its constituent neutrons and protons."
The 2021 edition of Fastlane would be the beginning of WWE phasing out the standalone WWE Network, with the company partnering with other platforms to distribute its content. Beginning with that edition of Fastlane in the United States, events began airing on NBCUniversal's streaming service, Peacock, following a merger of the American WWE Network under Peacock in March that year. The standalone version of the American WWE Network shut down on April 4. Over the next couple of years, other countries would see their own version of the WWE Network merge under other services. In Indonesia, the WWE Network merged under Disney+ Hotstar in January 2022, followed by a merger under Disney+ in the Philippines in November that year, while in Australia, it merged under Binge in January 2023 and then Abema in Japan that October. With this increased emphasis of digital platforms over traditional PPV outlets, WWE began to refer to all PPV and livestreaming events as "Premium Live Events" (PLEs), starting with the Day 1 event on January 1, 2022. In January 2025, the majority of the countries that still had the WWE Network merged under Netflix, with only a small number of countries maintaining the WWE Network due to pre-existing contracts. Beginning with Wrestlepalooza in September 2025, ESPN's direct-to-consumer streaming service assumed the streaming rights for main roster PLEs in the United States as part of a five-year deal following WWE's contract with Peacock. Also as part of the deal, select events also air on ESPN's linear channels.
Source 2 has also been used for Valve's Artifact and Dota Underlords, with the engine later being supported on Android and iOS for the latter. The engine also supports the creation of games in virtual reality, being used in SteamVR Home, the Robot Repair tech demo within The Lab, and Half-Life: Alyx. Source 2 tools made specifically for creating content for Half-Life: Alyx were released in May 2020.
Sources: en.wikipedia.org
Storage at -20 °C or below is standard for long-term stability. Desiccant and sealed containers limit moisture exposure. Solutions are prepared only when needed.
Reverse-phase HPLC separates components by hydrophobicity and reports purity as a percentage of total peak area. It does not by itself confirm molecular identity. Mass spectrometry is used alongside it for that purpose.
They link a specific lot to its analytical results and storage history. This traceability supports reproducibility when results differ between experiments. Records also help identify when re-testing is warranted.
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.